Blar i Bergen Open Research Archive på forfatter "Sorbye, Halfdan"
-
Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts
Osterlund, Emerik; Ristimäki, Ari; Mäkinen, Markus J.; Kytölä, Soili; Kononen, Juha; Pfeiffer, Per; Soveri, Leena-Maija; Keinänen, Mauri; Sorbye, Halfdan; Nunes, Luís; Salminen, Tapio; Nieminen, Lasse; Uutela, Aki; Halonen, Päivi; Ålgars, Annika; Sundström, Jari; Kallio, Raija; Ristamäki, Raija; Lamminmäki, Annamarja; Stedt, Hanna; Heervä, Eetu; Kuopio, Teijo; Sjöblom, Tobias; Isoniemi, Helena; Glimelius, Bengt; Osterlund, Pia (Journal article; Peer reviewed, 2023)BRAF-V600E mutation (mt) is a strong negative prognostic and predictive biomarker in metastatic colorectal cancer (mCRC). Non-V600Emt, designated atypical BRAFmt (aBRAFmt) are rare, and little is known about their frequency, ... -
CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup
Aasebø, Kristine; Dragomir, Anca; Sundström, Magnus; Mezheyeuski, Artur; Edqvist, Per-Henrik; Eide, Geir Egil; Pontén, Fredrik; Pfeiffer, Per; Glimelius, Bengt; Sorbye, Halfdan (Journal article; Peer reviewed, 2020-02-11)Background: Survival of metastatic colorectal cancer (mCRC) patients has improved, but mainly for trial patients. New predictive and prognostic biomarkers validated in the general mCRC population are needed. Caudal-type ... -
Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer
Hamfjord, Julian; Guren, Tormod Kyrre; Glimelius, Bengt; Sorbye, Halfdan; Pfeiffer, Per; Dajani, Olav; Lingjærde, Ole Christian; Tveit, Magne Kjell; Pallisgaard, Niels; Spindler, Karen-Lise Garm; Kure, Elin Wenche Hegland (Journal article; Peer reviewed, 2021)Detection of tumour-specific circulating cell-free DNA in plasma (ctDNA) fails in a significant number of cases depending on the clinical context. The primary aim was to investigate clinicopathological factors associated ... -
Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients
Aasebø, Kristine; Dragomir, Anca; Sundström, Magnus; Mezheyeuski, Artur; Edqvist, Per-Henrik; Eide, Geir Egil; Pontén, Fredrik; Pfeiffer, Per; Glimelius, Bengt; Sorbye, Halfdan (Peer reviewed; Journal article, 2019-05-09)Background: Immunotherapy for patients with microsatellite-instable (MSI-H) tumors or BRAF-inhibitors combination treatment for BRAF-mutated (mutBRAF) tumors in metastatic colorectal cancer (mCRC) is promising, but the ... -
Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study
Osterlund, P.; Kinos, S.; Pfeiffer, P.; Salminen, T.; Kwakman, J.J.M.; Frödin, J.-E.; Shah, C.H.; Sorbye, Halfdan; Ristamäki, R.; Halonen, P.; Soveri, L.M.; Heervä, E.; Ålgars, A.; Bärlund, M.; Hagman, H.; McDermott, R.; O'Reilly, M.; Röckert, R.; Liposits, G.; Kallio, R.; Flygare, P.; Teske, A.J.; van Werkhoven, Werkhoven; Punt, C.J.A.; Glimelius, B. (Journal article; Peer reviewed, 2022)Background Capecitabine- or 5-fluorouracil (5-FU)-based chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity. S-1 is a fluoropyrimidine with low rates of cardiotoxicity, but evidence ... -
Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
Meltzer, Sebastian; Negård, Anne; Bakke, Kine Mari; Hamre, Hanne Mari; Kersten, Christian; Hofsli, Eva; Guren, Marianne; Sorbye, Halfdan; Flatmark, Kjersti; Ree, Anne Hansen (Journal article; Peer reviewed, 2022)Background: Immune checkpoint blockade (ICB) results in radiologic tumour response dynamics that differ from chemotherapy efficacy measures and require an early signal of clinical utility. Methods: Previously untreated, ... -
The effect of BRAFV600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer – A post-hoc exploratory analysis of the randomized NORDIC9-study
Liposits, Gabor; Winther, Stine B.; Ryg, Jesper; Skuladottir, Halla; Möller, Sören; Hofsli, Eva; Shah, Carl-Henrik; Poulsen, Laurids Østergaard; Berglund, Åke; Qvortrup, Camilla; Osterlund, Pia; Glimelius, Bengt; Sorbye, Halfdan; Pfeiffer, Per (Journal article; Peer reviewed, 2023) -
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma
Sorbye, Halfdan; Grande, Enrique; Pavel, Marianne; Tesselaar, Margot; Fazio, Nicola; Reed, Nicholas Simon; Knigge, Ulrich; Christ, Emanuel; Ambrosini, Valentina; Couvelard, Anne; Tiensuu Janson, Eva (Journal article; Peer reviewed, 2023)This ENETS guidance paper, developed by a multidisciplinary working group, provides up-to-date and practical advice on the diagnosis and management of digestive neuroendocrine carcinoma, based on recent developments and ... -
Feminizing adrenal tumor identified by plasma steroid profiling
Vogt, Elinor Margrethe Chelsom; Hammerling, Katrin; Sorbye, Halfdan; Heie, Anette; Sulen, André; Ueland, Grethe Åstrøm; Husebye, Eystein Sverre; Methlie, Paal (Journal article; Peer reviewed, 2021)Feminizing estrogen-secreting adrenocortical carcinomas (ACCs) are exceedingly rare and carry a poor prognosis. The most common presenting trait is gynecomastia, but enlarged breasts are also a frequent clinical finding ... -
Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms
Venizelos, Andreas; Sorbye, Halfdan; Elvebakken, Hege; Perren, Aurel; Lothe, Inger Marie Bowitz; Couvelard, Anne; Hjortland, Geir Olav; Sundlöv, Anna; Svensson, Johanna; Garresori, Herish; Kersten, Christian; Hofsli, Eva; Detlefsen, Sönke; Vestermark, Lene W.; Ladekarl, Morten; Tabaksblat, Elizaveta Mitkina; Knappskog, Stian (Journal article; Peer reviewed, 2023)High-grade gastroenteropancreatic (HG-GEP) neuroendocrine neoplasms (NENs) are highly aggressive cancers. The molecular etiology of these tumors remains unclear, and the prevalence of pathogenic germline variants in patients ... -
A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer
Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Bjånes, Tormod Karlsen; Hoem, Dag; Schjøtt, Jan; Gjertsen, Bjørn Tore; Biermann, Martin; Molven, Anders; Sorbye, Halfdan; McCormack, Emmet; Postema, Michiel; Gilja, Odd Helge (Peer reviewed; Journal article, 2016-12)Background: The primary aim of our study was to evaluate the safety and potential toxicity of gemcitabine combined with microbubbles under sonication in inoperable pancreatic cancer patients. The secondary aim was to ... -
Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients
Larsen, Stein Gunnar; Goscinski, Mariusz Adam; Dueland, Svein; Steigen, Sonja Eriksson; Hofsli, Eva; Torgunrud, A.; Lund-Iversen, Marius; Dagenborg, Vegar Johansen; Flatmark, Kjersti; Sorbye, Halfdan (Journal article; Peer reviewed, 2021)Background Patients with metastatic colorectal cancer (mCRC) carrying BRAF (mutBRAF) or KRAS mutation (mutKRAS) have an inferior prognosis after liver or lung surgery, whereas the prognostic role in the context of peritoneal ... -
Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases
Løes, Inger Marie; Immervoll, Heike; Sorbye, Halfdan; Angelsen, Jon-Helge; Horn, Arild; Knappskog, Stian; Lønning, Per Eystein (Peer reviewed; Journal article, 2016-04)We determined prognostic impact of KRAS, BRAF, PIK3CA and TP53 mutation status and mutation heterogeneity among 164 colorectal cancer (CRC) patients undergoing liver resections for metastatic disease. Mutation status was ... -
KRAS-G12C mutation in one real-life and three population-based Nordic cohorts of metastatic colorectal cancer
Osterlund, Emerik; Ristimäki, Ari; Kytölä, Soili; Kuopio, Teijo; Heervä, Eetu; Muhonen, Timo; Halonen, Päivi; Kallio, Raija; Soveri, Leena-Maija; Sundström, Jari; Keinänen, Mauri; Ålgars, Annika; Ristamäki, Raija; Sorbye, Halfdan; Pfeiffer, Per; Nunes, Luís; Salminen, Tapio; Lamminmäki, Annamarja; Mäkinen, Markus J.; Sjöblom, Tobias; Isoniemi, Helena; Glimelius, Bengt; Osterlund, Pia (Journal article; Peer reviewed, 2022-02-16)Background: KRAS mutations, present in over 40% of metastatic colorectal cancer (mCRC), are negative predictive factors for anti-EGFR therapy. Mutations in KRAS-G12C have a cysteine residue for which drugs have been ... -
Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis
Nunes, Luís; Aasebø, Kristine; Mathot, Lucy; Ljungström, Viktor; Edqvist, Per-Henrik; Sundström, Magnus; Dragomir, Anca; Pfeiffer, Per; Ameur, Adam; Pontén, Fredrik; Mezheyeuski, Artur; Sorbye, Halfdan; Sjöblom, Tobias; Glimelius, Bengt (Journal article; Peer reviewed, 2020-01-10)Background: We have reported that BRAF V600E mutations and microsatellite instability-high (MSI-H) are more prevalent in a population-based cohort of metastatic colorectal cancer (mCRC) patients than has been reported from ... -
Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial
Labori, Knut Jørgen; Lassen, Kristoffer; Hoem, Dag; Grønbech, Jon Erik; Søreide, Jon Arne; Mortensen, Kim Erlend; Smaaland, Rune; Sorbye, Halfdan; Verbeke, Caroline Sophie; Dueland, Svein (Peer reviewed; Journal article, 2017-08-25)Background: Pancreatic cancer is the fourth leading cause of cancer-related death. While surgical resection remains the foundation for potentially curative treatment, survival benefit is achieved with adjuvant oncological ... -
Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
Janson, Eva Tiensuu; Knigge, Ulrich; Dam, Gitte; Federspiel, Birgitte; Grønbaek, Henning; Stålberg, Peter; Langer, Seppo W.; Kjaer, Andreas; Arola, Johanna; Schalin-Jäntti, Camilla; Sundin, Anders; Welin, Staffan; Thiis-Evensen, Espen; Sorbye, Halfdan (Journal article; Peer reviewed, 2021)Background The diagnostic work-up and treatment of patients with gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) has undergone major advances and new methods are introduced. Furthermore, an update of the WHO ... -
Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: A multicenter cohort study
Carlsen, Esben Andreas; Fazio, Nicola; Granberg, Dan; Grozinsky-Glasberg, Simona; Ahmadzadehfar, Hojjat; Grana, Chiara Maria; Zandee, Wouter T.; Cwikla, Jaroslaw; Walter, Martin A.; Oturai, Peter Sandor; Rinke, Anja; Weaver, Andrew; Frilling, Andrea; Gritti, Sara; Arveschoug, Anne Kirstine; Meirovitz, Amichay; Knigge, Ulrich; Sorbye, Halfdan (Peer reviewed; Journal article, 2019)Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrine tumors grade 1–2 (G1–G2). However, its possible benefit in high-grade gastroenteropancreatic (GEP) neuroendocrine neoplasms ... -
Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms
Morken, Siren; Langer, Seppo W.; Sundlöv, Anna; Vestermark, Lene Weber; Ladekarl, Morten; Hjortland, Geir Olav; Svensson, Johanna B.; Tabaksblat, Elizaveta Mitkina; Haslerud, Torjan Magne; Assmus, Jörg; Detlefsen, Sönke; Couvelard, Anne; Perren, Aurel; Sorbye, Halfdan (Journal article; Peer reviewed, 2023)Background The optimal treatment for metastatic high-grade gastroenteropancreatic (GEP) neuroendocrine neoplasms when Ki-67 ≤55% is unknown. A prospective multi-centre phase 2 study was performed to evaluate the efficacy ... -
Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors
Thiis-Evensen, Espen; Kjellman, Magnus; Knigge, Ulrich; Gronbaek, Henning; Schalin-Jäntti, Camilla; Welin, Staffan; Sorbye, Halfdan; del Pilar Schneider, Maria; Belusa, Roger (Journal article; Peer reviewed, 2022)There is an unmet need for novel biomarkers to diagnose and monitor patients with neuroendocrine neoplasms. The EXPLAIN study explores a multi-plasma protein and supervised machine learning strategy to improve the diagnosis ...